ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2011
Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 69 citations in OpenAlex.
- Hypoalbuminemia in children with cancer treated with chemotherapy.Pediatric blood & cancer · 2020Trial
- Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD.Bone marrow transplantation · 2015Trial
- Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.Haematologica · 2015Trial
- Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT.Bone marrow transplantation · 2013Trial
- 99mTc-HSA scintigraphy identifies protein-losing enteropathy in atypical GI-GVHD with modest diarrhea after allo-HSCT.International journal of hematology · 2026Article
- C-Reactive Protein/Albumin Ratio (CAR) Predicts Early Posttransplant Complications and Survival in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey.Bone marrow transplantation · 2025Article
- Article
- Effect of Short PSG Peptides on Inflammatory Markers in Allogeneic Bone Marrow Cell Transplantation in Wistar Rats.Bulletin of experimental biology and medicine · 2023Article
- Recent advances in graft-versus-host disease.Faculty reviews · 2023Review
- Prediction of outcomes after second-line treatment for acute graft-versus-host disease.Blood advances · 2022Article
- Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease.Frontiers in immunology · 2022Article
- Role of Biomarkers as Prognostic Factors in Acute Peripheral Facial Palsy.International journal of molecular sciences · 2021Review
- Favourable survival in "Discordant" acute gastrointestinal graft versus host disease (GI-GVHD) is explained by mild clinical course and treatment-responsive disease.International journal of hematology · 2020Article
- Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers.Bone marrow transplantation · 2020Article
- Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts.Annals of internal medicine · 2020Article
- Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2020Review
- Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis.Bone marrow transplantation · 2018Article
- Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Review
- Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.Nature reviews. Gastroenterology & hepatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Biomarkers capable of predicting the onset and severity of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT) would enable preemptive and risk-stratified therapy. Severe aGVHD leads to gastrointestinal protein loss, resulting in hypoalbuminemia. We hypothesized that decreases in serum albumin at onset of aGVHD would predict the risk of progression to severe aGVHD. We identified 401 patients who developed aGVHD grades II-IV after reduced-intensity allogeneic HCT and reviewed all available serum albumin values from 30 days before HCT to 45 days after initiation of treatment for aGVHD. A ≥0.5 g/dL decrease in serum albumin concentration from pretransplantation baseline to the onset of treatment for aGVHD predicted the subsequent development of grade III/IV aGVHD (versus grade II aGVHD) with a sensitivity of 69% and a specificity of 73%. Overall mortality at 6 months after initiation of aGVHD treatment was 36% versus 17% for patients with and without ≥0.5 g/dL decreases in serum albumin, respectively (P = .0009). We conclude that change in serum albumin concentration from baseline to initiation of aGVHD treatment is an inexpensive, readily available, and predictive biomarker of GVHD severity and mortality after reduced-intensity allogeneic HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.